1 Title:

2 SGLT2 inhibition reduces cardiac surgery-associated acute kidney injury: An

- **3 open-label randomized study.**
- 4 Short title:
- 5 MERCURI-1 trial
- 6 Authors:
- 7 Lars I.P. Snel^{1,2,3,9}, Maartina J.P. Oosterom-Eijmael^{1,2,3}, Elena Rampanelli^{3,4,5}, Yugeesh R.
- 8 Lankadeva^{6,7}, Mark P. Plummer^{7,8}, Benedikt Preckel^{1,9}, Jeroen Hermanides^{1,9}, Daniel H. van
- 9 Raalte^{2,3}, Abraham H. Hulst^{1,3,5}.
- 10 Affiliations:
- ¹ Department of Anesthesiology, Amsterdam University Medical Center, Amsterdam, The
- 12 Netherlands
- ² Department of Endocrinology, Amsterdam University Medical Center, Amsterdam, The
- 14 Netherlands
- 15 ³ Amsterdam Cardiovascular Sciences Research Institute, Amsterdam, the Netherlands
- ⁴ Department of Experimental Vascular Medicine, Amsterdam University Medical Center,
- 17 Amsterdam, The Netherlands
- ⁵ Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam, the
- 19 Netherlands

- ⁶ Preclinical Critical Care Unit, Florey Institute of Neuroscience and Mental Health, The
- 21 University of Melbourne, Melbourne, VIC, Australia.
- ⁷ Department of Critical Care, Melbourne Medical School, The University of Melbourne,
- 23 Melbourne, VIC, Australia.
- ⁸ Intensive Care Unit Research, Royal Adelaide Hospital, Adelaide, SA, Australia.
- ⁹ Amsterdam Public Health Research Institute, Quality of care, Amsterdam, the Netherlands

26 **Corresponding author**:

- 27 Maartina Oosterom-Eijmael
- 28 Department of Anesthesiology, Amsterdam UMC location AMC
- 29 Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
- 30 m.j.p.eijmael@amsterdamumc.nl
- 31 +31205669111
- 32 Total word count:
- 33 Abstract: 280
- 34 Total: 2872 (excluding title page, abstract, references, tables and figure legends)

35 Abstract

36 Background

37 Cardiac surgery-associated acute kidney injury (CSA-AKI) is a common postoperative 38 complication. Currently, no effective preventative strategies exist to mitigate CSA-AKI. Sodium-39 glucose transporter-2 (SGLT2) inhibitors reduced acute kidney injury (AKI) incidence in large, 40 randomized placebo-controlled, cardiovascular and kidney outcome trials conducted in patients 41 with chronic kidney disease. We hypothesized that perioperative SGLT2 inhibition could also 42 reduce CSA-AKI.

43 Methods

In this open-label phase IV, randomized, parallel-group, pilot study, adult patients undergoing 44 elective cardiac surgery with cardiopulmonary bypass were randomized to receive the SGLT2 45 46 inhibitor, empagliflozin (10 mg; oral), once daily three days prior to surgery and continued to 47 two days after surgery compared with standard-of-care. Biomarkers for acute kidney injury 48 (AKI), including serum and urinary neutrophil gelatinase-associated lipocalin (NGAL), serum and 49 urinary kidney injury molecule-1 (KIM-1), and serum hypoxia-inducible factor-1 α (HIF-1 α) were 50 measured. Additional outcomes included AKI incidence according to Kidney Disease: Improving 51 Global Outcomes (KDIGO) criteria as well as metabolic parameters, including ketone body 52 concentrations and glycemic control.

53

54

4

55 Results

56	Between March 2022 and April 2023, 55 patients were included (sex: 73% male, age: 66 ± 10
57	years, BMI: $28 \pm 4 \text{ kg/m}^2$, empagliflozin n = 25, control n = 30) in the intention-to-treat analysis.
58	Empagliflozin significantly reduced the incidence of AKI (20% vs 66.7%; absolute difference
59	46.7%, 95% CI, -69.7 – -23.6; P=.001). Following surgery, urinary NGAL, and KIM-1 were found
60	to increase in both arms, whereas a significant increment in serum HIF-1 α after surgery was
61	solely observed in the control group. We observed no between-group differences in the
62	incidence of (euglycemic) ketoacidosis or hypoglycemic events.
63	Conclusions
64	Perioperative SGLT2 inhibition, compared with standard of care, significantly reduced the
65	incidence of CSA-AKI. These findings warrant validation in large-scale, double-blind, placebo-
66	controlled, randomized trials.
67	Trial Registry:
68	https://onderzoekmetmensen.nl/en/trial/26563 Identifier: NL9561
69	
70	
71	
72	
73	

74 Clinical perspective:

75 What Is New?

- In this open-label, randomized, controlled, pilot trial perioperative use of sodium
- 77 glucose transporter-2 (SGLT2) inhibition with empagliflozin significantly reduced the
- 78 incidence of acute kidney injury (AKI) by 46.7% (95% CI, -69.7 -23.6; P=.001) compared

79 to the control group.

- The level of ketone bodies increased significantly during cardiac surgery, however, there
- 81 was no additional effect of empagliflozin treatment.

82 What Are the Clinical Implications?

- These results suggest that perioperative treatment with SGLT2 inhibitors might decrease
- 84 the risk of cardiac surgery-associated (CSA)-AKI.
- These findings warrant validation in large-scale, double-blind, placebo-controlled,
- 86 randomized trial, which is currently ongoing.

88 Non-standard Abbreviations and Acronyms

- 89 AKI: Acute kidney injury
- 90 CI: Confidence interval
- 91 CKD: Chronic kidney disease
- 92 CPB: Cardiopulmonary bypass
- 93 CSA-AKI: Cardiac surgery-associated acute kidney injury
- 94 eGFR: estimated glomerular filtration rate
- 95 HIF1α: Hypoxia-inducible factor 1 alpha
- 96 IU: International units
- 97 KIM-1: Kidney injury molecule 1
- 98 NGAL: Neutrophil gelatinase-associated lipocalin
- 99 KDIGO: Kidney Disease: Improving Global Outcomes
- 100 SGLT2: Sodium-glucose transporter-2
- 101 T1D: Type 1 diabetes
- 102 T2D: Type 2 diabetes
- 103
- 104

105 Introduction

Acute kidney injury (AKI) is a common complication following cardiac surgery, with a reported incidence of up to 70%. (1) Cardiac surgery-associated (CSA)-AKI is associated with postoperative morbidity and mortality, prolonged hospital stay, and increased healthcare costs. (2, 3) In addition, CSA-AKI can have long-term consequences, including the increased risk of developing chronic kidney disease (CKD) and reduced life expectancy compared to patients without CSA-AKI. (4-7)

Despite several attempts to prevent CSA-AKI with a variety of pharmacological interventions, no effective mitigation strategies have been developed to date. (2, 8, 9) Sodium-glucose transporter-2 (SGLT2) inhibitors have been reported to prevent AKI in large cardiovascular and kidney outcome trials in patients with or without type 2 diabetes (T2D). (10-13)

116 SGLT2 inhibitors reduce proximal sodium and glucose re-uptake, leading to an acute reduction in estimated glomerular filtration rate (eGFR) due to activation of tubuloglomerular feedback. 117 118 This reduction in eGFR leads to a lesser kidney workload. Lower filtered sodium load can reduce 119 kidney oxygen consumption, while SGLT2-induced improvements in insulin sensitivity and 120 substrate metabolism may further reduce kidney oxidative requirements. (14-16) SGLT2 121 inhibitors may be protective in settings of renal tissue hypoxia during cardiac surgery, which has 122 been directly reported in clinically relevant large animal models and in humans indirectly by 123 measurement of bladder urinary oxygenation. (17, 18) However, the safety of SGLT2 inhibitors 124 in cardiac surgery should also be considered, given the risk of SGLT2 inhibitor-associated 125 perioperative ketoacidosis caused by the fasted state and surgical stress. (19) This serious side

8

effect has prompted the Food and Drug Administration (FDA) to recommend interruption of SGLT2 inhibitors at least 3 days prior to major surgery. (19, 20) Here, we performed an openlabel, randomized, pilot study to evaluate the effects of SGLT2 inhibition on biomarkers of AKI, AKI incidence according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria and incidence of ketoacidosis and hypoglycemia in individuals undergoing cardiac surgery. We hypothesized that perioperative SGLT2 inhibition with empagliflozin would reduce both biomarkers of postoperative AKI and the incidence of AKI.

134 Methods

135 Trial design

136 We performed a prospective, single-center, open-label, phase IV, randomized, controlled 137 (standard care), balanced (1:1), pilot study. The study protocol was approved by the medical 138 ethics committee of the Amsterdam UMC and by the Dutch competent authority before the 139 initiation of the trial. The trial protocol was registered at the Dutch Trial Register 140 (https://www.onderzoekmetmensen.nl), number NTR9561. An independent study monitor 141 validated good clinical practice adherence and data collection quality. The study was conducted 142 in compliance with the latest version of the Declaration of Helsinki and Good Clinical Practice 143 guidelines. Neither a data safety management board nor a steering committee was involved in 144 the decision-making of this study. All participants signed informed consent prior to any trial-145 related activity.

146 **Study participants**

147 Patients eligible for inclusion were aged between 18 and 90 years and scheduled to undergo 148 elective cardiopulmonary bypass (CPB) assisted cardiac surgery at the Amsterdam University 149 Medical Centre (UMC), a tertiary academic hospital in the Netherlands. Exclusion criteria 150 included prior treatment with SGLT2 inhibitors, type 1 diabetes (T1D), T2D with a body mass 151 index (BMI) below 25 (possibly phenotypically resembling T1D), estimated glomerular filtration 152 rate (eGFR) <30 ml/min, systolic blood pressure below 100 mmHg, a history of ketoacidosis, a 153 known or suspected allergy to the trial product, or individuals who were breastfeeding, 154 intending to become pregnant or not using adequate contraceptive methods.

¹⁵⁵ 10

156 Intervention

157 After providing written informed consent, participants were randomly assigned to the 158 empagliflozin or control group. Patients in the empagliflozin group received a single dose of 159 empagliflozin 10 mg orally (Boehringer Ingelheim International GmbH via Alliance Healthcare 160 Nederland B.V.) every morning, starting from three days prior to surgery, until two days after 161 surgery. The control group received no intervention and received standard perioperative care. We initially intended to start empagliflozin treatment seven days before surgery, however, due 162 163 to logistical constraints in the planning of surgery, it became evident that this approach was not 164 feasible. Therefore, we adjusted the number of treatments before surgery in the protocol from 165 seven to three days prior to surgery before the recruitment of the first participant.

166 **Procedures**

167 Patients with T2D had their preoperative glucose management adjusted, if necessary, under the 168 supervision of an endocrinology consultant, according to the treatment algorithm shown in 169 Supplementary Figure 1. At the time of inclusion, on the morning of the day of surgery (before 170 the first incision), and on the first and second morning after surgery (D1 and D2), serum and 171 urine samples were collected to measure neutrophil gelatinase-associated lipocalin (NGAL), 172 kidney injury molecule (KIM)-1, hypoxia-inducible factor 1 alpha (HIF1 α) and creatinine. 173 Furthermore, arterial blood gases and ketone levels were collected at four specific time points 174 on the day of surgery: before the start of surgery (T1), at time of start of cardiopulmonary 175 bypass (T2), at the end of cardiopulmonary bypass (T3) and at time of transport to the intensive 176 care unit (ICU) (T4). As part of standard perioperative care, patients with insulin-dependent T2D

177 received a continuous glucose/insulin infusion preoperatively. In case ketoacidosis was 178 suspected based on increased anion gap metabolic acidosis with the presence of ketone bodies, 179 patients were to be treated with a mixed glucose/insulin infusion to suppress ketogenesis and 180 subsequently closely monitored and treated according to local practice. Postoperatively, 181 creatinine levels and urinary output were measured according to usual care (creatinine was 182 measured daily and urinary output hourly until the removal of the urinary catheter upon 183 patients' discharge from ICU). We also recorded glucose levels as measured during routine care 184 (four times daily during ICU admission) and insulin administrations when prescribed by the 185 treating physicians. Adverse events were collected by reviewing in-hospital electronic health records. The study workflow is summarized in Figure 1. 186

187 Outcomes

188 The primary outcome was the between-group difference of mean postoperative serum NGAL 189 concentrations measured on postoperative day two. Other outcomes included between-group 190 differences in any of the following measures: AKI incidence rates according to the KDIGO 191 criteria, postoperative urinary NGAL/creatinine ratios, serum KIM-1 concentrations, urinary 192 KIM-1/creatinine ratios, and serum HIF1 α levels. Additionally, we calculated the difference in 193 biomarker concentrations between the first and second postoperative days compared to the 194 day of surgery. Metabolic secondary outcomes include the between-group difference of 195 intraoperative ketone levels, the number of ketoacidosis events (defined as a combination of 196 ketonemia >3 mmol/l in combination with a high-anion gap metabolic acidosis), the mean 197 intraoperative glucose level, the mean peak postoperative glucose level measured in the first 198 48 hours postoperatively, the incidence of hypoglycemia (defined as glucose < 4.0 mmol/L), the

12

incidence of hyperglycemia (defined as glucose > 10.0 mmol/L) and the incidence of insulin
administrations. Additionally, we compared the length of stay in the ICU and postoperative inhospital complications such as mortality, renal replacement therapy, cerebrovascular accident
(CVA), cardiac tamponade, gastrointestinal bleeding, anemia requiring transfusion, atrial
fibrillation, other cardiac arrhythmia's, pacemaker implantations, infection of the mediastinum,
pneumonia, and delirium.

205 ELISA

Serum and urinary concentrations of NGAL and KIM-1 were measured with, respectively, the
LEGEND MAX[™] Human NGAL (Lipocalin-2) ELISA Kit (Biolegend, cat.N. 443407) and the human
KIM1 (TIM-1) ELISA Kit (ABCAM, cat.N. AB235081). Serum HIF-1A levels were detected using the
HIF1A Human ELISA Kit (Invitrogen, cat.N. EHIF1A). All measurements were performed after the
study had concluded and done according to the manufacturer's instructions. Urinary levels of
NGAL and KIM-1 were normalized for concentrations of creatinine, detected by standard tests
at the hospital laboratory of clinical chemistry.

213 Sample size

Based on a previous cohort study that found a difference in mean serum NGAL of 120 ng/ml between patients with and without AKI after cardiac surgery, we defined a between-group difference of 120 ng/ml in serum NGAL concentration on postoperative day 2 as a relevant outcome. (21) To detect a difference of 120 ng/ml, with 90% power, alpha at 0.05, we would need 40 patients per group.

219

13

220 Randomization and blinding

Randomization was performed electronically through the data management system Castor EDC (Ciwit BV, Amsterdam, the Netherlands) using balanced-block randomization, with variable-size random computer-generated blocks of two, four, or six and an allocation ratio of 1:1. By design (open-label study), patients, care providers nor study personnel were blinded to treatment allocation.

226 Statistical analyses

227 We performed all analyses on the intention-to-treat population. When biomarkers were below 228 the detection limit, we assigned the value of zero. Discrete data are presented as counts with 229 percentages per group. Continuous variables are presented as mean ± SD or median 230 (interguartile range), depending on the distribution of the data. Within-group comparisons 231 were conducted using the paired Student t-test. Between-group comparisons were performed 232 using Fisher's exact test for dichotomous outcomes and unpaired Student's t-test or Mann-233 Whitney U-tests for continuous variables, depending on the distribution of the data. Absolute 234 differences between groups are presented with their corresponding 95% confidence intervals 235 (95% CI). Repeated measurements were analyzed with generalized linear mixed models. To 236 compare between the treatment groups, we used the interaction term of the randomization 237 group with time. Additionally, we analyzed postoperative kidney biomarkers by calculating the 238 change in concentration compared to the day of surgery. Statistical analyses were performed 239 using SPSS (IBM version 24; IBM Corp., Armonk, New York).

240

14

241 Results

242 Between March 2022 and March 2023, we enrolled 60 patients planned to undergo cardiac 243 surgery, of which 29 patients were included in the empagliflozin group and 31 in the control 244 group (Figure 2). Before the start of the intervention, five patients were excluded (one 245 withdrew consent, two surgeries were cancelled for logistic reasons, and in two cases, the type 246 of surgery was changed, thereby not meeting the inclusion criteria). All remaining patients were 247 included in the intention-to-treat analysis (25 in the empagliflozin group, 30 in the control 248 group). All patients in the intervention group started with empagliflozin three days prior to 249 surgery.

Baseline characteristics of all included patients are summarized in Table 1. Overall, patient characteristics were well balanced between groups, except for age, with patients in the empagliflozin group being older. Patients were predominantly male, with relevant overweight, and had normal kidney function at baseline. T2D was present in 5 (9%) patients; none of them were treated with insulin therapy prior to hospital admission.

255 Kidney injury

The development of AKI characterized according to KDIGO criteria was observed in 5/25 (20%) patients in the empagliflozin group and 20/30 (66.7%) patients in the control group, with a difference of 46.7% between groups (95% CI, -69.7 – -23.6; P=.001) (Figure 3). In March 2023, the trial leadership team reviewed this significant between-group disparity in clinical outcomes. Concluding that these findings would require confirmation in a large, blinded and placebocontrolled trial, the trial leadership team ceased patient enrollment in this open-label pilot trial

and notified the medical ethics committee of trial termination. Upon completion of datacollection, blood and urine samples were sent for analysis.

264 Kidney biomarkers

265 Serum NGAL concentrations on the second postoperative day did not differ significantly between groups, empagliflozin: 70.8 ± 6.0 ng/ml vs control: 68.5 ± 10.0 ng/ml, with a difference 266 267 of 2.3 ng/ml (95% CI, -6.9 – 2.3; P=.317). Other biomarkers for kidney injury, including urinary 268 NGAL and KIM-1 in plasma and urine, did not demonstrate significant between-group 269 differences either (Figure 4). In contrast, we did observe a difference between study groups in 270 the development of serum HIF1 α in the perioperative period. In the control group, HIF1 α 271 increased significantly from 110 ± 152 ng/ml before surgery to 171 ± 182 ng/ml on the first day 272 after surgery (P=.04) and to 198 ± 268 ng/ml on the second day (P=.098). In contrast, in the 273 empagliflozin group, HIF1 α did not change from baseline levels in the postoperative period 274 (Figure 4). A complete overview of all biomarker concentrations is available in Supplementary 275 Table S1.

276 Metabolic effects

Ketone levels increased during surgery (Figure 5) in both groups; in 41 (76%) patients, the peak levels of ketones ($1.1 \pm 0.6 \text{ mmol/L}$) were measured at the end of CPB. The increase in ketone levels did not differ significantly between the groups. In the empagliflozin group, ketone levels increased by $1.0 \pm 0.5 \text{ mmol/L}$ compared to $0.8 \pm 0.5 \text{ mmol/L}$ in the control group, difference 0.2 mmol/L (95% CI, -0.5 - 0.1; P=.208). There was no significant difference in ketone

16

development between the groups (P value of the interaction term time*group = .75).
Ketoacidosis was not observed in any of the patients.

284 The mean intraoperative blood glucose was $6.6 \pm 1.1 \text{ mmol/L}$ in the empagliflozin group 285 compared to 7.1 \pm 1.5 mmol/L in the control group, difference 0.5 mmol/L (95% CI, -0.3 – 1.2; 286 P=.194). The intraoperative incidence of hyperglycemia, hypoglycemia, and insulin 287 administrations did not differ significantly between groups (Table 2). The peak glucose 288 concentration during the first 48 hours postoperative was 9.3 ± 1.5 mmol/L in the empagliflozin 289 group compared to $10.9 \pm 2.5 \text{ mmol/L}$ in the control group, difference of 1.6 mmol/L (95% Cl, 290 0.5 - 2.8; P=.007). During the postoperative period, the incidence of observed hyperglycemia 291 was 7/25 (28%) in the empagliflozin group compared to 18/30 (60%) in the control group, 292 difference 32% (95% CI, -56.8 - -7.2; P=.029). In the empagliflozin group, 2/25 (8%) patients 293 required insulin administrations due to hyperglycemia, compared to 11/30 (37%) patients in the 294 control group, with a difference of 29% between groups (95% CI, 8.4 – 48.9; P=.023). None of 295 the participants received insulin to treat ketoacidosis.

296 Adverse Events

297 No significant between-group differences were observed in the incidence of in-hospital 298 postoperative complications (Supplemental Table 2). The length of stay in ICU was 23 (19-42) 299 hours in the empagliflozin group compared to 32 (21-47) hours in the control group (P=.096).

300

17

301 Discussion

302 In this open-label, randomized controlled, pilot study we investigated the effect of SGLT2 303 inhibition with empagliflozin on CSA-AKI. This pilot study was prematurely stopped due to the 304 large between-group difference in AKI incidence; empagliflozin reduced the AKI incidence by 305 47% compared to the control group. HIF1 α levels significantly increased postoperatively in the 306 control group, whereas there was no significant change observed in the empagliflozin group. 307 AKI reduction was not reflected in changes in NGAL and KIM-1. Ketone bodies increased 308 significantly during surgery in both groups without an additional effect of empagliflozin. There 309 was no significant between-group difference in the incidence of hypoglycemia (which occurred 310 only once in the control group), while hyperglycemia was reduced.

311 CSA-AKI remains a frequent unresolved complication after cardiac surgery, with reported 312 incidences varying between 20% and 70%, depending on the type of surgery, the definition of 313 AKI used, and the protocol for AKI monitoring. (1) Our findings align with this high incidence, 314 exemplified by an incidence of AKI in the control group of 66.7%, which can be attributed to our 315 meticulous monitoring regimen of hourly urine output and daily creatinine measurements. This 316 study provides compelling evidence that perioperative SGLT2 inhibition with empagliflozin 317 offers protection against CSA-AKI. Our findings are in agreement with three meta-analyses 318 consistently demonstrating a reduction in AKI incidence in large-scale cardiovascular and kidney 319 outcome trials in outpatients. (10, 13, 22) The hypothesis that SGLT2 inhibitors provide kidney 320 protection comes from the theory that SGLT2 inhibitors reduce kidney workload and may, 321 therefore, improve kidney tissue oxygenation.

18

To estimate the effect of empagliflozin on kidney hypoxia responses, we measured HIF1 α levels, an established biomarker for hypoxia. We found that serum HIF1 α levels remained stable in the empagliflozin group, whereas HIF1 α increased in the control group after surgery. This is in line with earlier studies reporting that SGLT2 inhibition suppressed the HIF1- α pathway. (23, 24) Additionally, it has been shown (in mice) that SGLT2 inhibition after ischemia/reperfusion injury decreased the level of endothelial thinning, hypoxia, and the development of kidney fibrosis.(25)

While the clinical incidence of AKI was significantly lower after SGLT2 inhibition, this was not reflected by NGAL and KIM-1 differences. We selected serum and urinary NGAL and KIM-1 because they are widely studied biomarkers for AKI. (8) This study demonstrates that NGAL and KIM-1 do not reflect the kidney protective effects of SGLT2 inhibition following cardiac surgery.

333 In light of the FDA warning regarding the risk of ketoacidosis in patients perioperatively treated 334 with SGLT2 inhibitors, (26) we measured the development of ketones during surgery. We 335 observed a rise in ketone levels during surgery; however, no significant differences were 336 observed between treatment groups. In addition, none of the patients were diagnosed with 337 ketoacidosis during or after surgery. It is noteworthy that, by chance, insulin-dependent T2D 338 patients were not included in this study. Had they been included, the risk of ketoacidosis would 339 have been mitigated through the standard administration of glucose/insulin infusion 340 perioperatively for insulin-dependent T2D patients. Although the limited sample size cannot 341 prove safety, these findings are reassuring for further research. We also found no between-342 group differences in the incidence of hypoglycemia or other adverse events, while the risk for

19

343 hyperglycemia was even reduced. The lack of increased hypoglycemia fits the data from trials in344 patients with T2D.(27)

- 345 By design, this pilot study tested for feasibility and was limited by its sample size with a
- 346 standard care, open-label control group. As such, our findings warrant confirmation in a larger
- 347 placebo-controlled trial. Our group is currently leading such a large multi-center trial that will
- 348 include 784 patients undergoing cardiac surgery at multiple centers within the Netherlands and
- is estimated to complete enrollment in 2025. (clinicaltrials.gov: NCT05590143).

350 Conclusion

351 This pilot study indicates that SGLT2 inhibition may be a promising intervention for the 352 reduction of CSA-AKI, requiring confirmation in a larger placebo-controlled double-blinded 353 randomized controlled trial.

354

355 Acknowledgements

- 356 We extend our gratitude to all the participants who generously volunteered their time and
- 357 commitment to this trial. Furthermore, we want to thank all the dedicated research students
- 358 who were indispensable in the process of data collection: Hoang anh Nguyen, Phebe van
- 359 Straten, Mariam Zaouia, Yasmine Barkia, Gwen Blokhuis and Julika Kos.

360 **Details of authors' contributions**

- 361 Lars Snel: Investigation, Formal analysis, Validation, Writing Original Draft.
- 362 Maartina Oosterom-Eijmael: Investigation, Formal Analysis, Validation, Writing Original Draft.
- 363 Elena Rampanelli: Formal analysis, Validation, Resources.
- 364 Yugeesh Lankadeva: Writing Review & Editing, Supervision.
- 365 Mark Plummer: Writing Review & Editing.
- 366 Benedikt Preckel: Resources, Writing Review & Editing, Supervision.
- 367 Daniel van Raalte: Conceptualization, Methodology, Writing Review & Editing, Supervision.
- 368 Jeroen Hermanides: Conceptualization, Methodology, Writing Review & Editing, Supervision.
- 369 Abraham Hulst: Conceptualization, Methodology, Writing Review & Editing, Supervision,
- 370 Funding Acquisition.

371 Sources of Funding

372 "This project has received funding from the European Union's Horizon 2020

21

- 373 research and innovation program under the Marie Skłodowska-Curie grant
- 374 agreement No 101024833."
- 375 Disclosures
- 376 DHR has served as a consultant and received honoraria from Boehringer Ingelheim and Lilly,
- 377 Merck, Novo Nordisk, Sanofi, and AstraZeneca and has received research operating funds from
- 378 Boehringer Ingelheim and Lilly Diabetes Alliance, AstraZeneca, and NovoNordisk; all honoraria
- are paid to his employer (Amsterdam University Medical Center, Amsterdam). All other authors
- 380 declare no conflict of interests.

381 References

- 382 1. Chen JJ, Lee TH, Kuo G, Huang YT, Chen PR, Chen SW, et al. Strategies for post-cardiac
- 383 surgery acute kidney injury prevention: A network meta-analysis of randomized controlled
- trials. Front Cardiovasc Med. 2022;9:960581.
- 385 2. Schurle A, Koyner JL. CSA-AKI: Incidence, Epidemiology, Clinical Outcomes, and
- 386 Economic Impact. J Clin Med. 2021;10(24).
- 387 3. Prowle JR, Forni LG, Bell M, Chew MS, Edwards M, Grams ME, et al. Postoperative acute
- 388 kidney injury in adult non-cardiac surgery: joint consensus report of the Acute Disease Quality
- 389 Initiative and PeriOperative Quality Initiative. Nat Rev Nephrol. 2021;17(9):605-18.
- 390 4. Priyanka P, Zarbock A, Izawa J, Gleason TG, Renfurm RW, Kellum JA. The impact of acute
- kidney injury by serum creatinine or urine output criteria on major adverse kidney events in
- 392 cardiac surgery patients. The Journal of Thoracic and Cardiovascular Surgery. 2021;162(1):143-
- 393 51.e7.
- 394 5. Coca SG, Garg AX, Thiessen-Philbrook H, Koyner JL, Patel UD, Krumholz HM, et al.
- 395 Urinary biomarkers of AKI and mortality 3 years after cardiac surgery. J Am Soc Nephrol.
- 396 2014;25(5):1063-71.
- 397 6. Brown JR, Kramer RS, Coca SG, Parikh CR. Duration of acute kidney injury impacts long-
- term survival after cardiac surgery. Ann Thorac Surg. 2010;90(4):1142-8.
- 399 7. Hobson CE, Yavas S, Segal MS, Schold JD, Tribble CG, Layon AJ, et al. Acute Kidney Injury
- 400 Is Associated With Increased Long-Term Mortality After Cardiothoracic Surgery. Circulation.
- 401 2009;119(18):2444-53.

23

402 8. Ostermann M, Kunst G, Baker E, Weerapolchai K, Lumlertgul N. Cardiac Surgery

403 Associated AKI Prevention Strategies and Medical Treatment for CSA-AKI. J Clin Med.

404 2021;10(22).

405 9. Wang Y, Bellomo R. Cardiac surgery-associated acute kidney injury: risk factors,

406 pathophysiology and treatment. Nat Rev Nephrol. 2017;13(11):697-711.

407 10. Gilbert RE, Thorpe KE. Acute kidney injury with sodium-glucose co-transporter-2

408 inhibitors: A meta-analysis of cardiovascular outcome trials. Diabetes Obes Metab.

409 2019;21(8):1996-2000.

410 11. Menne J, Dumann E, Haller H, Schmidt BMW. Acute kidney injury and adverse renal

411 events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis. PLoS Med.

412 2019;16(12):e1002983.

413 12. Seki H, Ideno S, Shiga T, Watanabe H, Ono M, Motoyasu A, et al. Sodium-glucose

414 cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case

415 reports. J Anesth. 2023;37(3):465-73.

416 13. Nuffield Department of Population Health Renal Studies G, Consortium SiM-AC-RT.

417 Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney

418 outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet.

419 2022;400(10365):1788-801.

420 14. Ni L, Yuan C, Chen G, Zhang C, Wu X. SGLT2i: beyond the glucose-lowering effect.

421 Cardiovasc Diabetol. 2020;19(1):98.

422 15. D.H. van Raalte ACH, L.I.P. Snel, P.R. Scholten, L.A. Schwarte, R. Boellaard, P. Bjornstad.

423 Sodium-glucose cotransporter-2 inhibitors decreaes oxygen consumption in adults with type 2

24

424 diabetes: a randomised clinical trial using 11c-Acetate PET imaging. Proceedings of the 59th

425 Annual Meeting of the European Association for the Study of Diabetes. 2023.

426 16. Ghezzi C, Wright EM. Regulation of the human Na+-dependent glucose cotransporter

427 hSGLT2. Am J Physiol Cell Physiol. 2012;303(3):C348-54.

428 17. Hu RT, Lankadeva YR, Yanase F, Osawa EA, Evans RG, Bellomo R. Continuous bladder

429 urinary oxygen tension as a new tool to monitor medullary oxygenation in the critically ill. Crit

430 Care. 2022;26(1):389.

431 18. Lankadeva YR, Cochrane AD, Marino B, Iguchi N, Hood SG, Bellomo R, et al. Strategies

432 that improve renal medullary oxygenation during experimental cardiopulmonary bypass may

433 mitigate postoperative acute kidney injury. Kidney Int. 2019;95(6):1338-46.

434 19. Thiruvenkatarajan V, Meyer EJ, Nanjappa N, Van Wijk RM, Jesudason D. Perioperative

diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic

436 review. Br J Anaesth. 2019;123(1):27-36.

437 20. Yang JY, Wang T, Pate V, Buse JB, Sturmer T. Real-world evidence on sodium-glucose

438 cotransporter-2 inhibitor use and risk of Fournier's gangrene. BMJ Open Diabetes Res Care.

439 2020;8(1).

440 21. Parikh CR, Coca SG, Thiessen-Philbrook H, Shlipak MG, Koyner JL, Wang Z, et al.

441 Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac

442 surgery. J Am Soc Nephrol. 2011;22(9):1748-57.

443 22. Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for

the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-

445 analysis. The Lancet Diabetes & Endocrinology. 2019;7(11):845-54.

25

446 23. Bessho R, Takiyama Y, Takiyama T, Kitsunai H, Takeda Y, Sakagami H, et al. Hypoxia-

- 447 inducible factor- 1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy.
- 448 Scientific Reports. 2019;9(1).
- 449 24. Packer M. Mechanisms Leading to Differential Hypoxia-Inducible Factor Signaling in the
- 450 Diabetic Kidney: Modulation by SGLT2 Inhibitors and Hypoxia Mimetics. Am J Kidney Dis.
- 451 2021;77(2):280-6.
- 452 25. Zhang Y, Nakano D, Guan Y, Hitomi H, Uemura A, Masaki T, et al. A sodium-glucose
- 453 cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial
- 454 growth factor-dependent pathway after renal injury in mice. Kidney Int. 2018;94(3):524-35.
- 455 26. Administration USFD. FDA Drug Safety Communication: FDA revises labels of SGLT2
- 456 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary
- 457 tract infections, 2016 [cited 2024 19 February]. Available from:
- 458 https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-
- 459 diabetes-include-warnings-about-too-much-acid-blood-and-serious.
- 460 27. Saisho Y. SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes? Diseases.
- 461 2020;8(2).
- 462
- 463

464 Tables

465 **Table 1. Baseline characteristics of the intention-to-treat population.**

	All	Empagliflozin	Control
	(n=55)	(n=25)	(n=30)
Age, mean ± SD, years	66 ± 10	69 ± 8	63 ± 10
Male sex, n (%)	40 (73)	18 (72)	22 (73)
Ethnic origin, n (%)			
Caucasian	53 (96)	24 (96)	29 (97)
Other	2 (4)	1 (4)	1 (3)
BMI, mean ± SD, kg/m ²	28.0 ± 4.4	27.6 ± 3.4	28.2 ± 5.1
T2D, n (%)	5 (9)	3 (12)	2 (7)
Diabetes medication, n (%)			
Metformin	4 (7)	3 (12)	1 (3)
Sulfonylurea derivate	1 (2)	0 (0)	1 (3)
Hypertension, n (%)	28 (51)	13 (52)	15 (50)
NYHA classification, n (%)			
I	18 (33)	10 (40)	8 (27)
II	28 (51)	12 (48)	16 (53)
ш	9 (16)	3 (12)	6 (20)
LVEF, n (%)			
Good > 50%	40 (73)	20 (80)	20 (67)
Moderate 31-50%	15 (27)	5 (20)	10 (33)
ASA physical status classification, n (%)			
I	1 (2)	0 (0)	1 (3)
II	7 (13)	2 (8)	5 (17)

ш	45 (82)	22 (88)	23 (77)
IV	2 (4)	1 (4)	1 (3)
Creatinine clearance, mean ± SD, ml/min	70 ± 16	68 ± 16	73 ± 15
EuroSCORE II, mean ± SD, %	3.0 ± 3.2	2.8 ± 3.4	3.1 ± 3.0
Duration of surgery, mean ± SD, min	271 ± 96	249 ±83	291 ± 104
Type of surgery, n (%)			
CABG procedure	3(5.45)	1(4.0)	2 (6.67)
Single non-CABG procedure	28 (50.91)	12 (48)	16 (53.3)
Two or more procedures	24 (43.63)	12 (48)	12 (40)

ASA= American Society of Anesthesiologists; BMI= body mass index; CABG= coronary artery bypass graft; EuroSCORE= European System for Cardiac Operative Risk Evaluation; IQR= interquartile range; LVEF= left ventricular ejection fraction; NYHA= New York Heart Association; SD= standard deviation; T2D= type 2 diabetes

466

	Empagliflozin	Control	Absolute	95% CI	P value
	(n=25)	(n=30)	difference		
Intraoperative					
Mean blood glucose, mean ± SD, mmol/L	6.6 ± 1.1	7.1 ± 1.5	0.5	-0.3 - 1.2	0.194
Hyperglycemia (>10 mmol/L), n (%)	3 (12)	6 (20)	-8	-27.2 – 11.2	0.487
Hypoglycemia (<4 mmol/L), n (%)	0 (0)	1 (3)	-3.3	-9.8 - 3.1	1.000
Insulin administration, n (%)	1 (4)	2 (7)	-2.7	-14.4 - 9.1	1.000
Postoperative ^a					
Peak blood glucose, mean ± SD, mmol/L	9.3 ± 1.5	10.9 ± 2.5	1.6	0.5 – 2.8	0.007
Hyperglycemia (>10 mmol/L), n (%)	7 (28)	18 (60)	-32	-56.8 – -7.2	0.029
Hypoglycemia (<4 mmol/L), n (%)	0 (0)	0 (0)	NA	NA	NA
Insulin administration, n (%)	2 (8)	11 (37)	-29	-48.9 – -8.4	0.023

468 Table 2 Intraoperative and postoperative glycemic control and insulin administrations

CI= confidence interval; NA= not applicable; SD= standard deviation.^{*a}</sup> <i>The first 48 hours postoperative*</sup>

470 Figures



471 Figure 1. Summary of study workflow.

472

- 473 ABG= arterial blood gas; D1= first postoperative day; D2= second postoperative day; HIF1-alpha= Hypoxia-Inducible
- 474 Factor1-Alpha; KIM-1= Kidney Injury Molecule-1; LOS-ICU= length of stay in the Intensive Care Unit; NGAL=
- 475 Neutrophil Gelatinase-Associated Lipocalin; T1= before start of surgery; T2= at the start of cardiopulmonary
- 476 bypass; T3= at the end of cardiopulmonary bypass; T4= at time of transport to the intensive care unit.

478 Figure 2. CONSORT flowchart of patients in the study



485 Figure 3. Incidence rates of Acute Kidney Injury (AKI) across various stages compared



486 between the empagliflozin and control group.

	Empagliflozin	Control			
	25	30	Absolute difference	95% CI	P value
AKI, n (%)					
Stage 1	3 (12)	11 (36.7)	-24.7	-46.13.3	.061
Stage 2	1 (4)	8 (26.7)	-22.7	-40.35.1	.031
Stage 3	1 (4)	1 (3.3)	0.7	-9.3 - 10.7	1.000
Combined	5 (20)	20 (66.7)	-46.7	-69.723.6	.001

487

488 AKI= acute kidney injury; CI= confidence interval

490 Figure 4. Differences in postoperative kidney biomarkers concentrations compared to surgery



491 day for the empagliflozin and control group.

⁴⁹² HIF1-alpha= Hypoxia-Inducible Factor1-Alpha; KIM-1= Kidney Injury Molecule-1; NGAL= Neutrophil Gelatinase-

⁴⁹³ Associated Lipocalin.

495 **Figure 5. Intraoperative (mean ± SD) ketone levels.**



497 T1= before start of surgery; T2= at the start of cardiopulmonary bypass; T3= at the end of cardiopulmonary

498 *bypass;* T4= at time of transport to the intensive care unit)

499

500 Supplementary Tables

501 Supplementary Table 1. Kidney biomarkers were measured on surgery day and the first two

502 postoperative days.

		Empagliflozin	Control	Absolute	95% CI	Р
		(n=25)	(n=30)	Difference		value
Serum NGAL, (ng/ml)	D0	68.4 ± 6.0	66.3 ± 10.2	-2.1	-6.7 – 2.6	0.376
	D1	67.6 ± 11.4	65.4 ± 10.6	-2.2	-8.2 - 3.8	0.460
	D2	70.8 ± 6.0	68.5 ± 10.0	-2.3	-6.9 – 2.3	0.317
Urine NGAL/Creatinine (ng/mg)	D0	27.6 ± 58.2	9.0 ± 13.1	-18.6	-40.9 – 3.7	0.100
	D1	41.0 ± 74.0	21.8 ± 40.7	-19.2	-50.8 – 12.4	0.229
	D2	77.1 ± 120.8	41.2 ± 33.7	-35.9	-82.8 - 11.0	0.131
Serum KIM-1 (pg/ml)	D0	1458 ± 3843	1848 ± 4977	390	-2068 – 2849	0.751
	D1	841 ± 1694	1265 ± 3072	423	-636 – 1465	0.548
	D2	712 ± 1365	1126 ± 2300	414	-636 – 1465	0.432
Urine KIM-1/Creatinine (µg/mmol)	D0	0.2 ± 0.2	0.2 ± 0.1	0.0	-0.1 - 0.1	0.662
	D1	0.4 ± 0.3	0.4 ± 0.2	0.0	-0.1 - 0.2	0.893
	D2	0.7 ± 0.6	0.5 ± 0.2	-0.2	0.4-0.1	0.199
Serum HIF1α (pg/ml)	D0	142.7 ± 235.1	110.0 ± 151.6	-32.7	-139.3 – 73.9	0.541
	D1	129.5 ± 179.6	170.5 ± 182.5	41.0	-57.5 – 139.4	0.408
	D2	146.3 ± 134.7	198.1 ± 267.8	51.8	-66.5 – 170.1	0.384

Values are presented as mean \pm SD. CI= confidence interval; D0= day of surgery; D1= first postoperative day; D2= second postoperative day; HIF1 α = Hypoxia-Inducible Factor-1 alpha; KIM-1= Kidney Injury Molecule-1; NGAL= Neutrophil Gelatinase-Associated Lipocalin. SD= standard deviation

503

504

505 Supplementary Table 2. Overview of in-hospital adverse events

	Empagliflozin	Control	P value	506	-
	(n=25)	(n=30)			
Mortality, n (%)	1 (4)	0 (0)	0.455	507	-
Renal replacement therapy, n (%)	1 (4)	1 (3)	1.000	508	
CVA, n (%)	1 (4)	1 (3)	1.000	508	
Cardiac tamponade, n (%)	3 (12)	4 (13)	1.000	509	
Pericardial effusion, n (%)	0 (0)	1 (3)	1.000		
Thromboembolic events, n (%)	1 (4)	0 (0)	0.455	510	
Gastrointestinal bleeding, n (%)	1 (4)	0 (0)	0.455		
Anemia requiring transfusion, n (%)	2(8)	3 (10)	1.000	511	
Atrial fibrillation, n (%)	6 (24)	7 (23)	1.000	E10	
Other cardiac arrhythmia, n (%)	4 (16)	3 (10)	0.689	512	
Pacemaker implementation, n (%)	2 (8)	1 (3)	0.585	513	Abbr
Infection mediastinum, n (%)	2 (8)	0 (0)	0.202	514	eviati
Urinary tract infection, n (%)	1 (4)	0 (0)	0.455	515	ons:
Pneumonia, n (%)	1 (4)	0 (0)	0.455	516	CVA,
Delirium, n (%)	0 (0)	1 (3)	1.000	517	Cereb
				517	Cereb

518 rovascular accident

519

520

521

522

36

523 Supplemental Figures and Figure Legends

524 Supplemental Figure 1. Treatment algorithm for adjustment of antihyperglycemic therapy in

525 patients with a known history of type 2 diabetes



526

- 527 DPP4 inhibitors= Dipeptidyl Peptidase-4 inhibitors; GLP-1 RA= Glucagon-Like Peptide-1 Receptor Agonist; IU=
- 528 international units; SU= Sulfonylurea; T2D= Type 2 Diabetes